©2022 Stanford Medicine
Autologous Stem Cell Rescue for Primary Amyloidosis
Not Recruiting
Trial ID: NCT00186407
Purpose
To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for
amyloidosis.
Official Title
High Dose Chemotherapy and Autologous Stem Cell Rescue for Primary Amyloidosis
Stanford Investigator(s)
Sally Arai
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:1. Primary amyloidosis
2. Age < 75 years.
3. Patients must have their pathology reviewed and the diagnosis confirmed at Stanford
University Medical Center.
4. Patients who have undergone bone marrow transplantation previously will not be eligible.
5. Patients must have a Karnofsky performance status greater than 70%.
6. Patients must have a serum creatinine less than 2 mg/dl or creatinine clearance greater
than 30 ml/min, bilirubin less than 2 mg/dl, transaminases less than two times normal, left
ventricular ejection fraction >45% on echocardiography, cardiac index > 1.8 liters/min/m^2
and pulmonary function tests demonstrating FEV1 and DLCO > 60%.
7. Patients must be HIV negative.
8. Pregnant or lactating women will not be eligible to participate.
9. Patients must provide signed informed consent.
10. Patients with multiple myeloma and amyloid are eligible.
Exclusion Criteria:1. prior blood or marrow transplant
Intervention(s):
procedure: high dose chemo then auto hematopoietic cell transplant
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822